Full Press Release Details
MindMed to Participate at the Benzinga
Global Small Cap Conference
NEW YORK, December 2, 2021-- Mind
Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing
psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer, Robert Barrow, will provide a corporate
update and the Company's management will participate in one-on-one investor meetings at the Benzinga Global Small Cap Conference
to be held virtually on December 8-9, 2021.
Details on the conference can be found
Format: Corporate update and one-on-one
Date: Thursday, December 9, 2021
The webcast will also be accessible
in the "Investors" section of MindMed's website. MindMed will maintain an archived replay of the webcast on
its website for 30 days after the conference.
MindMed is a clinical-stage psychedelic
medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction
and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances
including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical
experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.
MindMed trades on the NASDAQ under the
symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.
Media Contact: media@mindmed.co
Investor Contact: ir@mindmed.co